Valuation : Theracryf Plc

Market Cap 5.51M 4.74M 4.45M 4.07M 7.6M 521M 7.66M 52.67M 20.51M 266M 20.71M 20.26M 858M P/E 2026 *
-1.28x
P/E 2027 * -1.71x
Enterprise Value 3.36M 2.89M 2.71M 2.48M 4.63M 317M 4.67M 32.07M 12.49M 162M 12.61M 12.33M 522M EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
54.35%
Yield 2026 *
-
Yield 2027 * -
1 day-2.63%
1 week-2.63%
Current month-2.63%
1 month-7.50%
3 months-22.92%
6 months-9.76%
Current year-7.50%
1 week 0.18
Extreme 0.18
0.2
1 month 0.16
Extreme 0.16
0.21
Current year 0.16
Extreme 0.16
0.27
1 year 0.16
Extreme 0.16
0.3
3 years 0.16
Extreme 0.16
2.52
5 years 0.16
Extreme 0.16
7.8
10 years 0.16
Extreme 0.16
33.1
Manager TitleAgeSince
Chief Executive Officer 64 01/10/2020
Director of Finance/CFO - 05/09/2023
Chief Tech/Sci/R&D Officer - 01/05/2021
Director TitleAgeSince
Director/Board Member - 14/10/2015
Director/Board Member 64 01/10/2020
Director/Board Member - 01/01/2024
Date Insider Type Main position Quantity % Market Cap. Importance
16/10/25
Tracarta Ltd.
BuyCompany 7,342,296 0.3448%
22/5/25 Others

Director

422,727,272 19.8499%
4/3/25 Buy

Chief Operating Officer

1,500,000 0.2945%
Change 5-day change 1-year change 3-year change Capi.($)
-2.63%-2.63%-26.00%-91.96% 5.51M
+1.03%-2.05%+39.28%+94.60% 68.87B
+1.31%+0.55%+49.48%+92.12% 65.29B
-1.07%+3.32%-12.60%+375.62% 27.65B
+2.97%-0.10%+41.86%+14.84% 25.77B
-0.68%-7.22%+2.93%-15.28% 26.08B
+1.01%+1.38%+26.48%-17.50% 20.14B
+3.45%-14.83%+225.22%+389.50% 17.03B
+0.77%-4.55%-0.36%+549.41% 15.03B
+1.75%+7.69%+61.01%+167.22% 14.5B
Average +0.80%-2.39%+40.73%+155.86% 28.04B
Weighted average by Cap. +1.09%-2.12%+42.76%+142.18%

Financials

2026 *2027 *
Net sales - -
Net income -3.38M -2.91M -2.73M -2.5M -4.66M -319M -4.7M -32.28M -12.57M -163M -12.69M -12.41M -526M -3.46M -2.98M -2.79M -2.55M -4.77M -327M -4.81M -33.03M -12.86M -167M -12.99M -12.7M -538M
Net Debt -2.16M -1.86M -1.74M -1.59M -2.97M -204M -3M -20.6M -8.02M -104M -8.1M -7.92M -336M -704K -606K -568K -520K -971K -66.54M -978K -6.72M -2.62M -34.01M -2.64M -2.59M -110M
Logo Theracryf Plc
TheraCryf plc is a clinical-stage drug development company focusing on brain disorders. The Company has a clinical and preclinical pipeline of indications, including addiction, anxiety, fatigue, narcolepsy, glioblastoma and neurodevelopmental disorders. Its lead program, orexin-1 antagonist, is being developed towards the clinic to target addictive behaviors like binge eating disorder (BED). It is also advancing a clinical-stage asset, SFX-01, in the fatal brain cancer glioblastoma (GBM). SFX-01 is a patented form of sulforaphane which has shown potential in the treatment of various cancers, neurodevelopmental disorders and other diseases. It has licensed the global rights for SFX-01 in neurodevelopmental disorders and schizophrenia to Stalicla. The Company also has a candidate molecule dopamine active transport (DAT) inhibitor at a late preclinical stage targeting fatigue and narcolepsy.
Employees
9
Date Price Change Volume
04/09/26 GBX 0.1850 -2.63% 4,371,430
02/09/26 GBX 0.1900 0.00% 593,023
01/09/26 GBX 0.1900 0.00% 405,000
28/08/26 GBX 0.1900 0.00% 1,799,771
27/08/26 GBX 0.1900 0.00% 668,009
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.002566USD
Average target price
0.0431USD
Spread / Average Target
+1,581.21%

Annual profits - Rate of surprise